Two Promising Healthcare Stocks to Consider: Eli Lilly and Intuitive Surgical

TL/DR –

The American healthcare sector reached $5.7 trillion in spending in 2025, a 7.3% increase from 2024, with expected continued expansion due to medical innovations and an aging population. This growth creates investment opportunities in companies like Eli Lilly and Intuitive Surgical. Eli Lilly leads in the fast-growing GLP-1 drug market and is expanding its portfolio through acquisitions and the use of artificial intelligence in drug development, while Intuitive Surgical, the market leader in robotic-assisted surgery (RAS), has great potential for expansion as the RAS market remains underpenetrated.


Surge in Healthcare Spending Boosts Eli Lilly and Intuitive Surgical

Healthcare spending in America rose by 7.3% last year, reaching $5.7 trillion. This growth, spurred by increased consumption of medical products and services coupled with an aging population, indicates a promising future for companies in the sector. Two such companies, Eli Lilly (LLY +2.97%) and Intuitive Surgical (ISRG 1.33%), show excellent potential for superior returns.

1. Eli Lilly

Some segments of the healthcare industry are set to expand faster than others, one being the GLP-1 drug market. Eli Lilly, a dominant player in this space, has seen strong sales thanks to its GLP-1 medicines, Mounjaro, Zepbound, and Foundayo. Furthermore, Eli Lilly is expected to maintain its lead as it has a robust pipeline of products in development that could expand its current market.

In addition to its GLP-1 drugs, Eli Lilly has broadened its portfolio through acquisitions and is poised to make significant strides in other areas. The company is also leveraging artificial intelligence for drug development, which could lead to cost reductions and increased profits in the long term. Consequently, Eli Lilly presents a lucrative investment opportunity for those looking to benefit from the healthcare sector’s growth.

2. Intuitive Surgical

Another promising company is Intuitive Surgical, a market leader in the rapidly growing field of Robotic-assisted surgery (RAS). The firm’s da Vinci system allows surgeons to perform minimally invasive procedures, resulting in less bleeding, scarring, and faster recovery times for patients.

Despite the potential competition and the impact of tariffs on its financial results, Intuitive Surgical maintains a leading position in the market, thanks to its wide moat and high switching costs. This robust position grants the company considerable pricing power, which it can use to offset tariff impacts by increasing prices. Therefore, despite recent challenges, Intuitive Surgical remains a strong contender for long-term success.

Disclosure: Prosper Junior Bakiny has positions in Eli Lilly, Intuitive Surgical, Johnson & Johnson, and Novo Nordisk. The Motley Fool recommends and holds positions in Eli Lilly, Intuitive Surgical, Merck, and Novo Nordisk. The Motley Fool also recommends Johnson & Johnson. The Motley Fool has a disclosure policy.


Read More Health & Wellness News ; US News